Pennsylvania Senate Bill SB1206

Pennsylvania 2025-2026 Regular Session

• Introduced: 3/30/26
• Refer: 3/30/26

Caption

Further providing for definitions and for license application.

Summary

SB1206 amends Pennsylvania’s Wholesale Prescription Drug Distributors License Act to revise the definition of “virtual manufacturer” and to change what information applicants must provide when seeking a license. Under the bill, a virtual manufacturer is a person with a place of business in Pennsylvania that manufactures and distributes a drug or medical device, holds the FDA approval/label code or is identified on the product label, or has already submitted an FDA application or intends to do so within 12 months, and that never takes physical possession of the product in Pennsylvania. The bill also adds new license-application requirements for manufacturers of prescription drugs that are not yet FDA-approved and for virtual manufacturers that do not yet hold FDA approval or label identification. In both cases, applicants must state that they have submitted an FDA application or intend to do so within 12 months. The Department may not require FDA approval of the drug or medical device as a condition of licensure under the act. The bill takes effect 60 days after enactment.

Impact

SB1206 would amend state licensing law governing wholesale prescription drug distributors by broadening and clarifying the category of “virtual manufacturer” and by limiting the Department’s ability to condition licensure on prior FDA approval. It affects manufacturers and virtual manufacturers of prescription drugs and medical devices operating in Pennsylvania, especially entities developing products that are not yet approved by the FDA but are moving toward approval.

Sentiment

No committee transcript or vote record is available, so there is no documented floor or committee debate to gauge sentiment. Based on the bill text, the measure appears to be aimed at facilitating licensing for emerging drug and device businesses and reducing regulatory barriers tied to FDA approval status.

Contention

The main point of potential contention is the bill’s restriction on the Department’s ability to require FDA approval before issuing a license. Supporters would likely view this as a pro-innovation and business-development change that helps Pennsylvania-based manufacturers and virtual manufacturers get licensed earlier in the product-development process. Opponents or regulators may be concerned that licensing entities before FDA approval could weaken oversight or create ambiguity around products that are still awaiting federal review.